Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07282587 · ClinicalTrials.gov registry record · Phase 2
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
A Phase 2 study of Advanced Pheochromocytoma and Paraganglioma and PCPG, sponsored by Jazz Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 9
- Study locations
NCT07282587: Recruiting Phase 2 study of Advanced Pheochromocytoma and Paraganglioma and PCPG, sponsored by Jazz Pharmaceuticals.
NCT07282587 is a Phase 2 study of Advanced Pheochromocytoma and Paraganglioma and PCPG that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07282587, a Phase 2 study of Advanced Pheochromocytoma and Paraganglioma and PCPG, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).
Primary Outcome
ORR defined as the number of participants with a confirmed complete response (CR) or partial response during the study, as per RECIST v1.1.
Conditions Studied
Interventions
- DRUG ONC206
- DRUG ONC206: Dose 1
- DRUG ONC206: Dose 2
Study Locations (9)
California
- UCLA - Los Angeles
- Stanford - Palo Alto
Colorado
- U of Colorado - Aurora
Michigan
- U of Michigan - Ann Arbor
Minnesota
- Mayo-Rochester - Rochester
Missouri
- Washington University - St Louis
New York
- Columbia University Medical Center - New York
Pennsylvania
- PENN - Philadelphia
Utah
- UTAH - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-01-02 |
| Est. Completion | 2028-12-15 |
| Phase | Phase 2 |
What NCT07282587 shows while recruiting
NCT07282587 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 2 conditions, with Advanced Pheochromocytoma and Paraganglioma appearing as the primary indexed condition, and to 3 interventions - of which ONC206 is the first listed.
NCT07282587 lists 9 locations in 8 states (California, Colorado, Michigan).
Frequently Asked Questions
What is clinical trial NCT07282587 about?
NCT07282587 is a clinical study titled "Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma". This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).
What is the current status of trial NCT07282587?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-01-02. Estimated completion is 2028-12-15.
What conditions does trial NCT07282587 study?
This clinical trial studies the following conditions: Advanced Pheochromocytoma and Paraganglioma, PCPG.
What interventions are being tested in trial NCT07282587?
The interventions under investigation include: ONC206 (DRUG), ONC206: Dose 1 (DRUG), ONC206: Dose 2 (DRUG).
Who is sponsoring clinical trial NCT07282587?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07282587 being conducted?
This trial has 9 study locations across California, Colorado, Michigan, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07282587's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI